Company PureTech Health plc

Equities

PRTC

GB00BY2Z0H74

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per Business

Ratings for PureTech Health plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 07:05:26 2024-05-21 am EDT			5-day change	1st Jan Change
229.8 ^GBX	+0.55%		+4.27%	+19.46%

May. 20	PureTech Health Opens $100 Million Buyback Program	MT
May. 20	PureTech Health plc announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million.	CI

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

Number of employees: 90

GBP in Million	2022	Weight	2023	Weight	Delta
Parent Company and Other 51.9 %	0	3.3 %	1	51.9 %	+236.22%
Wholly-Owned Programs 25.6 %	2	18.1 %	1	25.6 %	-70.09%
Controlled Founded Entities 22.5 %	10	78.1 %	1	22.5 %	-93.91%

GBP in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	13	100.0 %	3	100.0 %	-78.87%

Managers	Title	Age	Since
Eric Elenko FOU	Founder	51	15-05-31
Bharatt Chowrira CEO	Chief Executive Officer	59	17-03-01
Allison Talbot IRC	Investor Relations Contact	-	16-03-31
Anita Terpstra PRN	Corporate Officer/Principal	-	-
Aleksandra Filipovic PRN	Corporate Officer/Principal	-	15-08-31
Robert Lyne PRN	Corporate Officer/Principal	41	Jan. 30

Members of the board	Title	Age	Since
Raju S. Kucherlapati CHM	Chairman	81	13-12-31
Bharatt Chowrira CEO	Chief Executive Officer	59	17-03-01
Robert Langer FOU	Founder	75	15-05-07
John LaMattina BRD	Director/Board Member	74	08-12-31
Kiran Mazumdar-Shaw BRD	Director/Board Member	71	20-09-30
Sharon Barber-Lui BRD	Director/Board Member	-	22-03-23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	288,027,173	231,041,607 ( 80.22 %)	17,614,428 ( 6.116 %)	80.22 %

Name	Equities	%	Valuation
Invesco Asset Management Ltd. 24.04 %	64,945,474	24.04 %	176 M p
Lansdowne Partners (UK) LLP 9.019 %	24,371,115	9.019 %	66 M p
Baillie Gifford & Co. 8.335 %	22,521,433	8.335 %	61 M p
Jupiter Asset Management Ltd. 5.273 %	14,247,071	5.273 %	39 M p
Daphne Zohar 4.705 %	12,712,671	4.705 %	34 M p
M&G Investment Management Ltd. 4.353 %	11,761,956	4.353 %	32 M p
Miller Value Partners LLC 3.714 %	10,035,100	3.714 %	27 M p
Eurizon Capital SGR SpA 3.539 %	9,564,000	3.539 %	26 M p
RECORDATI 3.536 %	9,554,140	3.536 %	26 M p
Patient Capital Management, Inc. 3.516 %	9,500,000	3.516 %	26 M p

Name	Equities	%	Valuation
Pentwater Capital Management LP 0.0629 %	17,000	0.0629 %	473 620 p
AWM Investment Co., Inc. 0.0255 %	6,900	0.0255 %	192 234 p
Tower Research Capital LLC 0.000507 %	137	0.000507 %	3 817 p
UBS Financial Services, Inc. 0.000074 %	20	0.000074 %	557 p

PureTech Health Plc

6 Tide Street Suite 400

02210, Boston

+617 482 2333

https://puretechhealth.com

Name	Category and Sector
Puretech Health LLC Puretech Health LLC Investment ManagersFinance Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts.	Investment Managers

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.903 USD

Average target price

6.205 USD

Spread / Average Target

+113.75%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PURETECH HEALTH PLC	+17.66%	786M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.62%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research